May 3 2004 For most teens, getting a tan during spring break or in preparation for the prom is as common as these rites of passage themselves.
May 3 2004 With the incidence of skin cancer on the rise, it has never been more important for the public to practice the prevention and detection steps
May 3 2004 Progen Industries Limited, an Australian anti-cancer drug development company, announced today that it has received orphan drug designation from the U.
May 5 2004 The concept seems straightforward. If, at its heart, cancer is a disease of genes, then giving patients new genes should disarm cancer.
Restrictions by health insurers and government to control expenses may hurt the malignant melanoma drug market
May 12 2004 Decision Resources, Inc., a research and advisory firms focusing on pharmaceutical and health care issues, finds that restrictions by health
May 12 2004 Maxim Pharmaceuticals has announced the results of an international Phase 3 clinical trial testing the combination of Ceplene (TM) plus interleukin-2
May 24 2004 An innovative drug with a new mechanism of action that may be effective against a range of cancers will enter the first phase of clinical trials
Jun 2 2004 Genentech, Inc. and Roche have announced that the New England Journal of Medicine published the first Phase III study of an anti-angiogenesis
Jun 3 2004 The nation’s leading cancer organizations report that Americans’ risk of getting and dying from cancer continues to decline and
Jun 5 2004 Roche OSI Pharmaceuticals and Genentech today announced that their investigational drug Tarceva(TM) (erlotinib) achieved a significant 42.